Linked Life Data

12598839

Source:http://linkedlifedata.com/resource/pubmed/id/12598839

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2003-2-24
pubmed:abstractText
Surgery is still the first line of therapy for endometriosis. At present, medical therapy is mostly indicated for treatment and prevention of recurrences. Current pharmacological regimens induce a hypoestrogenic state; this effect tends, on one hand, to inhibit the growth of endometriotic implants while, on the other hand, it significantly interferes with the integrity of the hypothalamus-pituitary-ovarian axis. The aim of this study is to review current knowledge on the new experimental therapeutic approaches to the disease. English articles on this topic have been searched by Medline. A particular attention has been paid to experimental therapeutic interventions supported by in vivo results. Three different novel strategies have been identified: 1) To act on estrogenic dependence of endometriosis using new drugs such as aromatase inhibitors and raloxifene. These drugs may have the advantage to act more specifically on the disease. 2) To treat the disease with immuno-modulators and anti-inflammatory drugs. These compounds may be helpful in both limiting the growth of endometriotic implants and in controlling the symptoms of the disease. 3) To prevent adhesion reformation after surgical lysis. Adhesions are an important hallmark of endometriosis which cannot be adequately eliminated by surgery. The use of barrier and fluid agents after surgical lysis seems to be effective in this regard. Results from studies aimed to investigate the effectiveness of these approaches are appealing. However, controlled clinical trials are now required to appropriately determine their real benefits and their specific indications.
pubmed:language
ita
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0026-4784
pubmed:author
pubmed:issnType
Print
pubmed:volume
55
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
15-23
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed-meshheading:12598839-Adjuvants, Immunologic, pubmed-meshheading:12598839-Animals, pubmed-meshheading:12598839-Anti-Inflammatory Agents, pubmed-meshheading:12598839-Aromatase Inhibitors, pubmed-meshheading:12598839-Clinical Trials as Topic, pubmed-meshheading:12598839-Drug Evaluation, Preclinical, pubmed-meshheading:12598839-Endometriosis, pubmed-meshheading:12598839-Enzyme Inhibitors, pubmed-meshheading:12598839-Estrogen Receptor Modulators, pubmed-meshheading:12598839-Female, pubmed-meshheading:12598839-Humans, pubmed-meshheading:12598839-Hypothalamo-Hypophyseal System, pubmed-meshheading:12598839-Mice, pubmed-meshheading:12598839-Mice, Inbred BALB C, pubmed-meshheading:12598839-Mice, Inbred C57BL, pubmed-meshheading:12598839-Papio, pubmed-meshheading:12598839-Pregnancy, pubmed-meshheading:12598839-Pregnancy Rate, pubmed-meshheading:12598839-Raloxifene, pubmed-meshheading:12598839-Rats, pubmed-meshheading:12598839-Recurrence, pubmed-meshheading:12598839-Selective Estrogen Receptor Modulators, pubmed-meshheading:12598839-Tissue Adhesions
pubmed:year
2003
pubmed:articleTitle
[The therapy of endometriosis. New prospects].
pubmed:affiliation
II Clinica Ostetrico-Ginecologica, Clinica Luigi Mangiagalli, Università degli Studi di Milano, Milan, Italy.
pubmed:publicationType
Journal Article, English Abstract, Review